November 1, 1990The Journal of Clinical Pharmacology
Reassessment of Benefit—Risk Ratio and Treatment Algorithms for Antiarrhythmic Drug Therapy After the Cardiac Arrhythmia Suppression Trial
Population
Patients with cardiac arrhythmias, including asymptomatic postinfarction arrhythmias, malignant ventricular…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May warrant avoiding Class IC agents post-MI; leaves open optimal strategies in contemporary reperfusion cohorts.
Structured PICO
P
Population
Patients with cardiac arrhythmias, including asymptomatic postinfarction arrhythmias, malignant ventricular arrhythmias, and symptomatic nonmalignant ventricular arrhythmias
I
Intervention
Antiarrhythmic drug therapy (including Class IC agents, beta blockers, amiodarone, sotalol, and Class IA/IB agents)
Following the CAST trial, the prophylactic use of Class IC antiarrhythmic drugs for asymptomatic postinfarction arrhythmias is contraindicated, fundamentally shifting treatment algorithms toward more conservative approaches and beta-blocker use.
Cite This Study
Jeffrey L. Anderson (1990) studied this question.